Equities research analysts forecast that BioScrip Inc (NASDAQ:BIOS) will post sales of $185.73 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for BioScrip’s earnings. The lowest sales estimate is $185.46 million and the highest is $186.00 million. BioScrip posted sales of $175.79 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 5.7%. The company is expected to issue its next quarterly earnings results on Tuesday, August 6th.
On average, analysts expect that BioScrip will report full-year sales of $752.83 million for the current year, with estimates ranging from $752.66 million to $753.00 million. For the next fiscal year, analysts anticipate that the business will report sales of $802.56 million, with estimates ranging from $796.00 million to $809.11 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for BioScrip.
BioScrip (NASDAQ:BIOS) last posted its earnings results on Thursday, May 2nd. The company reported ($0.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. The business had revenue of $178.96 million during the quarter, compared to the consensus estimate of $179.23 million. The business’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.12) earnings per share.
Shares of NASDAQ BIOS traded down $0.04 during trading hours on Thursday, hitting $2.16. 1,021,300 shares of the stock were exchanged, compared to its average volume of 1,247,701. The company has a market cap of $275.54 million, a P/E ratio of -4.41 and a beta of 0.49. BioScrip has a one year low of $1.56 and a one year high of $4.14.
A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in BioScrip by 28.8% during the 4th quarter. BlackRock Inc. now owns 9,807,734 shares of the company’s stock valued at $35,013,000 after purchasing an additional 2,191,490 shares during the last quarter. Vanguard Group Inc raised its stake in BioScrip by 0.5% during the 3rd quarter. Vanguard Group Inc now owns 5,987,679 shares of the company’s stock valued at $18,562,000 after purchasing an additional 27,904 shares during the last quarter. Vanguard Group Inc. raised its stake in BioScrip by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,987,679 shares of the company’s stock valued at $18,562,000 after purchasing an additional 27,904 shares during the last quarter. Rothschild & Co. Asset Management US Inc. raised its stake in BioScrip by 68.1% during the 1st quarter. Rothschild & Co. Asset Management US Inc. now owns 3,812,471 shares of the company’s stock valued at $7,625,000 after purchasing an additional 1,545,050 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in BioScrip by 9.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,865,990 shares of the company’s stock valued at $5,731,000 after purchasing an additional 248,969 shares during the last quarter. Hedge funds and other institutional investors own 78.98% of the company’s stock.
BioScrip Company Profile
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.
See Also: What are gap-up stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.